Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

188.61B

Market cap188.61B

Price-Earnings ratio

24.45

Price-Earnings ratio24.45

Dividend yield

2.78%

Dividend yield2.78%

Average volume

2.95M

Average volume2.95M

High today

$363.30

High today$363.30

Low today

$348.50

Low today$348.50

Open price

$351.80

Open price$351.80

Volume

337.50K

Volume337.50K

52 Week high

$391.29

52 Week high$391.29

52 Week low

$261.43

52 Week low$261.43

Stock Snapshot

Amgen(AMGN) stock is priced at $349.88, giving the company a market capitalization of 188.61B. It carries a P/E multiple of 24.45 and pays a dividend yield of 2.8%.

As of 2026-03-23, Amgen(AMGN) stock has fluctuated between $348.50 and $363.30. The current price stands at $349.88, placing the stock +0.4% above today's low and -3.7% off the high.

Amgen(AMGN) shares are trading with a volume of 337.5K, against a daily average of 2.95M.

During the past year, Amgen(AMGN) stock moved between $261.43 at its lowest and $391.29 at its peak.

AMGN News

Simply Wall St 4d

Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Risks And Valuation

Amgen and Kyowa Kirin have discontinued all clinical trials of rocatinlimab after newly identified safety risks, including malignancy cases. The decision remov...

TipRanks 4d

Amgen Expands Oncology Pipeline With New Phase 1 AMG 436 Study in MSI-H/dMMR Tumors

Amgen Inc (AMGN) announced an update on their ongoing clinical study. The Phase 1/1b study “A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmac...

TipRanks 4d

Amgen price target raised to $390 from $375 at Wells Fargo

Wells Fargo raised the firm’s price target on Amgen to $390 from $375 and keeps an Equal Weight rating on the shares. The firm thinks new drugs and mechanisms s...

Analyst ratings

53%

of 38 ratings

Buy

39.5%

Hold

52.6%

Sell

7.9%

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.